Skip to main content

IDENTIFICACION DE UNA HUELLA MOLECULAR BASADA EN BIOMARCADORES EN LA INSUFICIENCIA CARDIACA CON ENFERMEDAD RENAL CRONICA. IMPLICACIONES MECANISTICAS, PRONOSTICAS Y TERAPEUTICAS.

PI20/01319

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2020
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INSTITUTO DE INVESTIGACION SANITARIA DE NAVARRA
Execution centre INSTITUTO DE INVESTIGACION SANITARIA DE NAVARRA (IdISNA)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Fibrosis Biomarker Early Predicts Cardiotoxicity Due to Anthracycline-Based Breast Cancer Chemotherapy

  • de la Fuente, Ana
  • Santisteban, Marta|||0000-0003-0625-686X
  • Lupón, Josep|||0000-0002-5601-9611
  • Aramendía, José Manuel|||0000-0002-6417-4267
  • Díaz, Agnes
  • Santaballa, Ana|||0000-0001-7763-320X
  • Hernándiz, Amparo
  • Sepúlveda, Pilar|||0000-0001-6071-7431
  • Cediel, Germán|||0000-0001-9667-7507
  • López, Begoña
  • Picazo, José María López
  • Mazo, Manuel M.|||0000-0002-6250-5579
  • Rábago, Gregorio
  • Gavira, Juan José
  • García-Bolao, Ignacio
  • Díez, Javier|||0000-0002-3414-6919
  • González, Arantxa|||0000-0001-5986-6528
  • Bayés-Genís, Antoni|||0000-0002-3044-197X
  • Ravassa, Susana
Left ventricular dysfunction (LVD) induced by anthracycline-based cancer chemotherapy (ACC) is becoming an urgent healthcare concern. Myocardial fibrosis (MF) may contribute to LVD after ACC. We show that elevated circulating levels of procollagen type I C-terminal propeptide (PICP, biomarker of MF) are associated with early subclinical LVD and predict later development of cardiotoxicity in patients treated with ACC. In addition, an association between PICP and LVD in patients with ACC-induced heart failure is observed. These results provide novel insights into MF as a mechanism underlying LVD after ACC, with PICP emerging as a promising tool to monitor cardiotoxicity in patients treated with ACC. Anthracycline-based cancer chemotherapy (ACC) causes myocardial fibrosis, a lesion contributing to left ventricular dysfunction (LVD). We investigated whether the procollagen-derived type-I C-terminal-propeptide (PICP): (1) associates with subclinical LVD (sLVD) at 3-months after ACC (3m-post-ACC); (2) predicts cardiotoxicity 1-year after ACC (12m-post-ACC) in breast cancer patients (BC-patients); and (3) associates with LVD in ACC-induced heart failure patients (ACC-HF-patients). Echocardiography, serum PICP and biomarkers of cardiomyocyte damage were assessed in two independent cohorts of BC-patients: CUN (n = 87) at baseline, post-ACC, and 3m and 12m (n = 65)-post-ACC; and HULAFE (n = 70) at baseline, 3m and 12m-post-ACC. Thirty-seven ACC-HF-patients were also studied. Global longitudinal strain (GLS)-based sLVD (3m-post-ACC) and LV ejection fraction (LVEF)-based cardiotoxicity (12m-post-ACC) were defined according to guidelines. BC-patients: all biomarkers increased at 3m-post-ACC versus baseline. PICP was particularly increased in patients with sLVD (interaction- p < 0.001) and was associated with GLS (p < 0.001). PICP increase at 3m-post-ACC predicted cardiotoxicity at 12m-post-ACC (odds-ratio ≥ 2.95 per doubling PICP, p ≤ 0.025) in both BC-cohorts, adding prognostic value to the early assessment of GLS and LVEF. ACC-HF-patients: PICP was inversely associated with LVEF (p = 0.004). In ACC-treated BC-patients, an early increase in PICP is associated with early sLVD and predicts cardiotoxicity 1 year after ACC. PICP is also associated with LVD in ACC-HF-patients.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Transcriptomic analysis of extracellular vesicles in the search for novel plasma and thrombus biomarkers of ischemic stroke etiologies

  • Machado, Florencio J.D.
  • Marta-Enguita, Juan
  • Gómez, Susan U.
  • Rodríguez, José Antonio
  • Páramo, José A.
  • Herrera, María
  • Zandio, Beatriz
  • Aymerich, Nuria
  • Muñoz, Roberto
  • Bermejo, Rebeca
  • Marta-Moreno, Javier
  • López, Begoña
  • González, Arantxa
  • Roncal Mancho, Carmen
  • Orbe, Josune
Accurate etiologic diagnosis provides an appropriate secondary prevention and better prognosis in ischemic stroke (IS) patients; still, 45% of IS are cryptogenic, urging us to enhance diagnostic precision. We have studied the transcriptomic content of plasma extracellular vesicles (EVs) (n = 21) to identify potential biomarkers of IS etiologies. The proteins encoded by the selected genes were measured in the sera of IS patients (n = 114) and in hypertensive patients with (n = 78) and without atrial fibrillation (AF) (n = 20). IGFBP-2, the most promising candidate, was studied using immunohistochemistry in the IS thrombi (n = 23) and atrium of AF patients (n = 13). In vitro, the IGFBP-2 blockade was analyzed using thromboelastometry and endothelial cell cultures. We identified 745 differentially expressed genes among EVs of cardioembolic, atherothrombotic, and ESUS groups. From these, IGFBP-2 (cutoff > 247.6 ng/mL) emerged as a potential circulating biomarker of embolic IS [OR = 8.70 (1.84–41.13) p = 0.003], which was increased in patients with AF vs. controls (p < 0.001) and was augmented in cardioembolic vs. atherothrombotic thrombi (p < 0.01). Ex vivo, the blockage of IGFBP-2 reduced clot firmness (p < 0.01) and lysis time (p < 0.001) and in vitro, diminished endothelial permeability (p < 0.05) and transmigration (p = 0.06). IGFBP-2 could be a biomarker of embolic IS and a new therapeutic target involved in clot formation and endothelial dysfunction., This research was funded by Instituto de Salud Carlos III, ISCIII (PI22/00436, PI21/00946 and PI20/01319) and co-funded by the European Regional Development Fund, ERDF, “A way to make Europe”; CIBERCV (CB16/11/00483); RICORS-ICTUS (RD21/0006/0008), Government of Navarra (MINERVA II) and Virto S.A.